Skip to main content

Table 1 Clinical characteristics of the patients in the discovery study in survivors and non-survivors at 28 days

From: Circulating neutrophil counts and mortality in septic shock

  Total (n = 195) Survivors (n = 125) Non-survivors (n = 70) P
Patient details     
     Gender (male) 125 (64.1%) 79 (63.2%) 46 (65.7%) NS
     Age (years) 71.6 ± 11.1 70.2 ± 11.1 74.2 ± 10.7 0.014
     Hypertension 109 (55.9%) 71 (56.8%) 38 (54.3%) NS
     Cardiovascular disease 87 (44.6%) 54 (43.2%) 33 (47.1%) NS
     Cancer 44 (22.5%) 21 (16.8%) 23 (32.8%) 0.010
     COPD 33 (16.9%) 24 (19.2%) 9 (12.8%) NS
     Diabetes 31 (15.9%) 24 (19.2%) 7 (10%) NS
     Obesity 32 (16.4%) 21 (16.8%) 11 (15.7%) NS
     Smoker 27 (13.8%) 17 (13.6%) 10 (14.2%) NS
     Chronic renal failure 26 (13.3%) 15 (12.0%) 11 (15.7%) NS
     Alcohol abuse 12 (6.1%) 8 (6.4%) 4 (5.7%) NS
     Inmunosuppression 9 (4.6%) 5 (4.0%) 4 (5.7%) NS
     Hepatic disease 6 (3.1%) 4 (3.2%) 2 (2.8%) NS
Clinical status at admission     
     APACHE II 14.7 ± 5.9 13.9 ± 5.8 16.2 ± 5.9 0.013
     Mechanical ventilation 134 (68.7%) 83 (66.4%) 51 (72.9%) NS
     OARF 41 (21.0%) 19 (15.2%) 22 (31.4%) 0.008
Presumed source of infection     
     Digestive system 115 (58.9%) 76 (60.8%) 39 (55.7%) NS
     Respiratory system 19 (9.7%) 14 (11.2%) 5 (7.1%) NS
     Central nervous system 20 (10.2%) 14 (11.2%) 6 (8.5%) NS
     Urinary system 10 (5.1%) 5 (4.0%) 5 (7.1%) NS
     Endocardium 7 (3.5%) 5 (4.0%) 2 (2.8%) NS
     Catheter 34 (17.4%) 26 (20.8%) 8 (11.4%) NS
     Wound/skin, soft tissue 28 (14.3%) 20 (16.0%) 8 (11.4%) NS
     Other/unknown 55 (28.2%) 35 (28.0%) 20 (28.5%) NS
Type of surgery     
     Abdominal 99 (50.7%) 56 (44.8%) 43 (61.4%) 0.030
     Cardiac 71 (36.4%) 54 (43.2%) 17 (24.3%)
     Other 25 (12.8%) 15 (12.0%) 10 (14.3%)
Urgent surgery     
     Yes 130 (66.6%) 77 (61.6)% 53 (75.7%) 0.045
Documented microbial agent     
     Gram-negative 67 (41.6%) 48 (44.4%) 19 (35.8%) NS
     Gram-positive 68 (42.2%) 47 (43.5%) 21 (39.6%) NS
     Fungi 24 (14.9%) 16 (14.8%) 8 (15.1%) NS
Laboratory data     
     Bilirubin (mg/dL) 1.4 ± 1.3 1.5 ± 1.4 1.2 ± 1.0 NS
     Glycemia (mg/dL) 166.4 ± 65.1 165.4 ± 58.3 168.2 ± 76.0 NS
     Procalcitonin (ng/mL) 19.3 ± 32.5 16.5 ± 28.6 24.3 ± 38.1 NS
     CRP (mg/mL) 231.8 ± 119.2 221.9 ± 106.6 249.4 ± 138.1 NS
     INR 1.7 ± 0.9 1.6 ± 0.9 1.7 ± 0.8 NS
     Platelets (×103/μl) 190.2 ± 140.0 196.9 ± 143.5 178.2 ± 133.5 NS
     Leukocytes (×103/μl) 16.3 ± 10.1 16.4 ± 9.0 16.2 ± 11.7 NS
     Monocytes (×103/μl) 0.7 ± 0.4 0.7 ± 0.4 0.6 ± 0.5 NS
     Lymphocyte (×103/μl) 1.1 ± 0.7 1.1 ± 0.8 1.0 ± 0.6 NS
     Neutrophils (×103/μl) 14.4 ± 9.4 14.4 ± 8.4 14.3 ± 11.1 NS
     Basophils (×103/μl) 0.1 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 NS
     Eosinophils (×103/μl) 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 NS
  1. For the demographic characteristics of the patients, differences between groups were assessed using the χ2 test for categorical variables and the Student's t-test for continuous variables when appropriate. Continuous variables are expressed as mean ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; INR, international normalized ratio; NS, not significant; OARF, oliguric acute renal failure.